insights_auto
Outlook: 86.1% bullish·2.8% bearish
Go to analysischevron_right
CSL:ASX
CSL Ltd
A$181.46
arrow_downward
-0.29%(-0.53) 1D
Oct 8, 4:10:19 PM GMT+11 · AUD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CSL...
Open
A$185.00
High
A$185.00
Low
A$180.20
Mkt. cap
86.06B
Avg. vol.
1.17M
Volume
679.97K
Dividend
1.56%
Quarterly dividend
A$0.71
Ex-dividend date
Sep 11, 2023
52-wk high
A$222.47
52-wk low
A$90.00
EPS
-A$7.68
Shares outstanding
479.88M
No. of employees
29K
Open
A$185.00
High
A$185.00
Low
A$180.20
Mkt. cap
86.06B
Avg. vol.
1.17M
Volume
679.97K
Dividend
1.56%
Quarterly dividend
A$0.71
Ex-dividend date
Sep 11, 2023
52-wk high
A$222.47
52-wk low
A$90.00
EPS
-A$7.68
Shares outstanding
479.88M
No. of employees
29K
News stories
From web sources and news partners
AD HOC NEWS
·
2 hours ago
CSL stock loses 0.40 percent after-hours to EUR 112.14
StreetInsider
·
3 hours ago
Haemonetics stock surges 17% on CSL Plasma supply deal update
Yahoo Finance
·
5 hours ago
Haemonetics shares jump as CSL sets 2027 rollout of plasma devices
marketscreener.com
·
7 hours ago
Haemonetics Shares Gain as CSL Targets Rollout of Company's Devices by End of 2027
Profile
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994. Wikipedia
About CSL Ltd
CEOPaul McKenzie
Employees29K
Founded1916
HeadquartersMelbourne, Victoria, Australia
SectorBiotechnology
Websitecsl.com